Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:OCUL NASDAQ:SLDB NASDAQ:SPRY NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeOCULOcular Therapeutix$9.92+3.2%$8.22$5.79▼$11.78$1.58B1.431.42 million shs2.16 million shsSLDBSolid Biosciences$5.24+6.7%$3.86$2.41▼$10.37$406.15M2.341.20 million shs1.90 million shsSPRYARS Pharmaceuticals$16.95-0.8%$14.91$8.91▼$18.90$1.66B0.91.34 million shs1.30 million shsVERAVera Therapeutics$23.00+0.1%$22.73$18.53▼$51.61$1.47B1.19989,734 shs833,816 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceOCULOcular Therapeutix+2.67%+3.56%+6.54%+59.63%+44.08%SLDBSolid Biosciences-1.33%+0.82%+8.15%+83.90%-16.35%SPRYARS Pharmaceuticals+3.67%-2.06%+17.94%+38.61%+87.80%VERAVera Therapeutics-3.26%-2.50%+1.19%+21.79%-35.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationOCULOcular Therapeutix3.9175 of 5 stars3.51.00.04.12.92.50.0SLDBSolid Biosciences3.1297 of 5 stars4.62.00.00.00.62.50.6SPRYARS Pharmaceuticals3.2084 of 5 stars3.61.00.00.03.24.20.6VERAVera Therapeutics3.3346 of 5 stars4.61.00.00.02.04.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceOCULOcular Therapeutix 3.00Buy$17.3374.73% UpsideSLDBSolid Biosciences 3.17Buy$15.10188.17% UpsideSPRYARS Pharmaceuticals 3.17Buy$31.0082.89% UpsideVERAVera Therapeutics 3.10Buy$65.00182.61% UpsideCurrent Analyst Ratings BreakdownLatest SLDB, VERA, SPRY, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/26/2025SLDBSolid BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$14.006/17/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.006/6/2025SLDBSolid BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.006/3/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/3/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/2/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $65.006/2/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $85.005/29/2025OCULOcular TherapeutixHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.005/22/2025SLDBSolid BiosciencesCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$16.005/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookOCULOcular Therapeutix$63.72M24.80N/AN/A$2.01 per share4.94SLDBSolid Biosciences$8.09M50.20N/AN/A$3.43 per share1.53SPRYARS Pharmaceuticals$97.12M17.14N/AN/A$2.64 per share6.42VERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateOCULOcular Therapeutix-$193.51M-$1.15N/AN/AN/A-323.09%-59.92%-41.98%8/6/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.99N/AN/AN/AN/A-68.15%-55.33%8/12/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.16N/AN/AN/A-16.11%-6.94%-5.60%8/5/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.00N/AN/AN/AN/A-40.59%-34.54%8/6/2025 (Estimated)Latest SLDB, VERA, SPRY, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025SPRYARS Pharmaceuticals-$0.42N/AN/AN/A$12.92 millionN/A5/15/2025Q1 2025SLDBSolid Biosciences-$0.53-$0.59-$0.06-$0.59N/AN/A5/14/2025Q1 2025SPRYARS Pharmaceuticals-$0.35-$0.35N/A-$0.35$7.48 million$7.97 million5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthOCULOcular TherapeutixN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioOCULOcular Therapeutix0.2610.2210.14SLDBSolid BiosciencesN/A10.8910.89SPRYARS Pharmaceuticals0.3011.0010.74VERAVera Therapeutics0.1027.6827.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipOCULOcular Therapeutix59.21%SLDBSolid Biosciences81.46%SPRYARS Pharmaceuticals68.16%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipOCULOcular Therapeutix2.30%SLDBSolid Biosciences13.63%SPRYARS Pharmaceuticals33.50%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableOCULOcular Therapeutix230159.30 million155.64 millionOptionableSLDBSolid Biosciences10077.51 million66.95 millionOptionableSPRYARS Pharmaceuticals9098.21 million65.31 millionOptionableVERAVera Therapeutics4063.77 million53.38 millionOptionableSLDB, VERA, SPRY, and OCUL HeadlinesRecent News About These CompaniesVera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA NephropathyJuly 6 at 4:38 AM | msn.comVera Therapeutics Inc Class A Sustainability - MorningstarJuly 5 at 10:09 PM | morningstar.comMVera Therapeutics (NASDAQ:VERA) Shares Gap Up on Insider Buying ActivityJune 28, 2025 | americanbankingnews.comVera Therapeutics director Enright buys shares worth $5.2mJune 27, 2025 | investing.comVor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in FundingJune 27, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Up Following Insider Buying ActivityJune 26, 2025 | marketbeat.comInsider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of StockJune 26, 2025 | insidertrades.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Purchases 40,607 SharesJune 25, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Director Patrick G. Enright Acquires 209,393 SharesJune 25, 2025 | marketbeat.comPolycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsightJune 24, 2025 | theglobeandmail.comBAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsightJune 24, 2025 | finance.yahoo.comVera Therapeutics, Inc. (NASDAQ:VERA) Given Consensus Recommendation of "Buy" by BrokeragesJune 20, 2025 | marketbeat.comJ.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)June 19, 2025 | theglobeandmail.comVera Therapeutics, Inc. (NASDAQ:VERA) Short Interest UpdateJune 18, 2025 | marketbeat.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)...June 12, 2025 | marketbeat.comCantor Fitzgerald Comments on VERA FY2026 EarningsJune 11, 2025 | marketbeat.comQ2 EPS Estimates for Vera Therapeutics Increased by WedbushJune 11, 2025 | marketbeat.comVera Therapeutics Inc.June 10, 2025 | barrons.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 9, 2025 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 5.2% - Here's What HappenedJune 9, 2025 | marketbeat.comOtsuka, Vera stake their claims to IgAN treatmentJune 9, 2025 | pharmaphorum.comPNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendTop 3 Bank Stocks to Watch as Fed Rate Cuts LoomBy Chris Markoch | June 25, 2025View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom5 Small Cap Stocks With Explosive Upside PotentialBy Ryan Hasson | June 23, 2025View 5 Small Cap Stocks With Explosive Upside PotentialSarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesBy Leo Miller | June 18, 2025View Sarepta Drops 42% on Fatalities; Markets Eye Solid BiosciencesSLDB, VERA, SPRY, and OCUL Company DescriptionsOcular Therapeutix NASDAQ:OCUL$9.92 +0.31 (+3.23%) Closing price 04:00 PM EasternExtended Trading$9.68 -0.24 (-2.47%) As of 05:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Solid Biosciences NASDAQ:SLDB$5.24 +0.33 (+6.72%) Closing price 04:00 PM EasternExtended Trading$5.39 +0.15 (+2.84%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.ARS Pharmaceuticals NASDAQ:SPRY$16.95 -0.14 (-0.82%) Closing price 04:00 PM EasternExtended Trading$16.94 -0.01 (-0.06%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.Vera Therapeutics NASDAQ:VERA$23.00 +0.03 (+0.13%) Closing price 04:00 PM EasternExtended Trading$23.00 0.00 (0.00%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.